Edoxaban, a direct factor Xa inhibitor, is the latest of the non-vitamin K antagonist oral
anticoagulants (NOACs). Despite being marketed later than other NOACs, its use is now …

The direct oral anticoagulants (DOACs), dabigatran, rivaroxaban, apixaban, and edoxaban,
are becoming the most commonly prescribed drugs for preventing ischemic stroke in …

Aims Edoxaban, a novel factor Xa inhibitor, is a substrate of cytochrome P450 3 A4
(CYP3A4) and the efflux transporter P‐glycoprotein (P‐gp). Three edoxaban drug–drug …

Vitamin K antagonists (VKAs) remain the standard therapy for anticoagulation in prevention
and treatment of venous thromboembolism (VTE) and for the prevention of stroke in atrial …

Long-term anticoagulation treatment with warfarin has been associated with a number of
limitations in clinical practice and there is a need for more convenient long-term …

Vitamin K antagonists have been the cornerstone of oral antithrombotic therapy to help
prevent ischemic stroke in atrial fibrillation (AF) and reduce venous thromboembolic events …

Background Edoxaban recently proved non-inferior to warfarin for prevention of
thromboembolism in patients with non-valvular atrial fibrillation (AF). We conducted an …

Direct oral anticoagulants (DOACs) are novel direct-acting medications that are selective for
either thrombin or activated factor X. Due to their obvious benefits for patients (fewer …

The use of warfarin, the most commonly prescribed oral anticoagulant, is being questioned
by clinicians worldwide due to warfarin several limitations (a limited therapeutic window and …

N. Matsushima 1, F. Lee 2, T. Sato 1, D. Weiss 2, J. Mendell 1 1 Daiichi Sankyo Pharma
Development, 2 Celerion Purpose: Edoxaban is a selective, oral direct factor Xa inhibitor …